Advertisement

World Journal of Urology

, Volume 37, Issue 12, pp 2623–2629 | Cite as

Stereotactic ablative radiation therapy for oligometastatic prostate cancer delays time-to-next systemic treatment

  • C. Leigh Moyer
  • Ryan Phillips
  • Matthew P. Deek
  • Noura Radwan
  • Ashley E. Ross
  • Emmanuel S. Antonarakis
  • Diane Reyes
  • Jean Wright
  • Stephanie A. Terezakis
  • Daniel Y. Song
  • Curtiland DeVille
  • Patrick C. Walsh
  • Theodore L. DeWeese
  • Michael Carducci
  • Edward M. Schaeffer
  • Kenneth J. Pienta
  • Mario Eisenberger
  • Phuoc T. TranEmail author
Topic Paper

Abstract

Purpose

Local ablative treatment to oligometastatic patients can result in long-term disease-free survival in some cancer patients. The importance of this treatment paradigm in prostate cancer is a rapidly evolving field. Herein, we report on the safety and preliminary clinical outcomes of a modern cohort of oligometastatic prostate cancer (OPC) patients treated with consolidative stereotactic ablative radiation (SABR).

Methods

Records of men with OPC who underwent consolidative SABR at our institution were reviewed. SABR was delivered in 1–5 fractions of 5–18 Gray. Kaplan–Meier estimates of local progression-free survival (LPFS), biochemical progression-free survival (bPFS; PSA nadir + 2), distant progression-free survival (DPFS), and time-to-next intervention (TTNI) were calculated.

Results

In total, 66 OPC patients were identified with consolidative SABR delivered to 134 metastases: 89 bone, 40 nodal, and 5 viscera. The majority of men (49/66) had hormone-sensitive prostate cancer (HSPC). Crude grade 1 and 2 acute toxicities were 36% and 11%, respectively, with no ≥ grade 3 toxicity. At 1 year, LPFS was 92% and bPFS and DPFS were 69%. Of the 18 men with HSPC who had deferred hormone therapy , 11 (56%) remain disease free following SABR (1-year ADT-FS was 78%). In 17 castration-resistant men, 11 had > 50% prostate-specific antigen (PSA) declines with 1-year TTNI of 30%.

Conclusions

Consolidative SABR in OPC is feasible and well tolerated. The heterogeneity and small size of our series limit extrapolation of clinically meaningful outcomes following consolidative SABR in OPC, but our preliminary data suggest that this approach warrants continued prospective study.

Keywords

Oligometastatic prostate cancer Stereotactic ablative radiation therapy Androgen-deprivation therapy 

Notes

Acknowledgements

PT Tran was supported by the Nesbitt-McMaster Foundation, Ronald Rose & Joan Lazar; Movember Foundation, Prostate Cancer Foundation; Commonwealth Foundation; NIH/NCI (R01CA166348 and U01CA2120007).

Author contributions

CLM data collection or management, data analysis, and manuscript writing/editing. RP data collection or management, data analysis, and manuscript writing/editing. MPD manuscript writing/editing. NR data collection or management, data analysis, and manuscript writing/editing. AER protocol/project development, data collection or management, and manuscript writing/editing. ESA protocol/project development, data collection or management, and manuscript writing/editing. DR protocol/project development, data collection or management, and manuscript writing/editing. JW data collection or management and manuscript writing/editing. SAT data collection or management and manuscript writing/editing. DYS protocol/project development, data collection or management, and manuscript writing/editing. CD protocol/project development, data collection or management, and manuscript writing/editing. PCW protocol/project development and data collection or management. TLD protocol/project development and data collection or management. MC protocol/project development and data collection or management. EMS protocol/project development and data collection or management. KJP protocol/project development, data collection or management, and manuscript writing/editing. ME protocol/project development, data collection or management, data analysis, and manuscript writing/editing. PTT protocol/project development, data collection or management, data analysis, and manuscript writing/editing

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Research involving human participants and/or animals

For this type of study, formal consent is not required.

Informed consent

For this type of study, formal consent is not required.

Supplementary material

345_2018_2477_MOESM1_ESM.docx (112 kb)
Supplementary material 1 (DOCX 111 kb)

References

  1. 1.
    Hellman S, Weichselbaum RR (1995) Oligometastases. J Clin Oncol 13(1):8–10CrossRefGoogle Scholar
  2. 2.
    Tosoian JJ, Gorin MA, Ross AE, Pienta KJ, Tran PT, Schaeffer EM (2017) Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations. Nat Rev Urol 14(1):15–25CrossRefGoogle Scholar
  3. 3.
    Uppal A, Wightman SC, Mallon S, Oshima G, Pitroda SP, Zhang Q, Huang X, Darga TE, Huang L, Andrade J, Liu H, Ferguson MK, Greene GL, Posner MC, Hellman S, Khodarev NN, Weichselbaum RR (2015) 14q32-encoded microRNAs mediate an oligometastatic phenotype. Oncotarget 6(6):3540–3552CrossRefGoogle Scholar
  4. 4.
    Wong AC, Watson SP, Pitroda SP, Son CH, Das LC, Stack ME, Uppal A, Oshima G, Khodarev NN, Salama JK, Weichselbaum RR, Chmura SJ (2016) Clinical and molecular markers of long-term survival after oligometastasis-directed stereotactic body radiotherapy (SBRT). Cancer 122(14):2242–2250CrossRefGoogle Scholar
  5. 5.
    Reyes DK, Pienta KJ (2015) The biology and treatment of oligometastatic cancer. Oncotarget 6(11):8491–8524CrossRefGoogle Scholar
  6. 6.
    Palma DA, Salama JK, Lo SS, Senan S, Treasure T, Govindan R, Weichselbaum R (2014) The oligometastatic state—separating truth from wishful thinking. Nat Rev Clin Oncol 11(9):549–557CrossRefGoogle Scholar
  7. 7.
    Gomez DR, Blumenschein GR Jr, Lee JJ, Hernandez M, Ye R, Camidge DR, Doebele RC, Skoulidis F, Gaspar LE, Gibbons DL, Karam JA, Kavanagh BD, Tang C, Komaki R, Louie AV, Palma DA, Tsao AS, Sepesi B, William WN, Zhang J, Shi Q, Wang XS, Swisher SG, Heymach JV (2016) Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol 17(12):1672–1682CrossRefGoogle Scholar
  8. 8.
    Iyengar P, Wardak Z, Gerber DE, Tumati V, Ahn C, Hughes RS, Dowell JE, Cheedella N, Nedzi L, Westover KD, Pulipparacharuvil S, Choy H, Timmerman RD (2018) Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial. JAMA Oncol 4(1):e173501CrossRefGoogle Scholar
  9. 9.
    Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, De Bruycker A, Lambert B, Delrue L, Bultijnck R, Claeys T, Goetghebeur E, Villeirs G, De Man K, Ameye F, Billiet I, Joniau S, Vanhaverbeke F, De Meerleer G (2018) Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol 36(5):446–453CrossRefGoogle Scholar
  10. 10.
    Collen C, Christian N, Schallier D, Meysman M, Duchateau M, Storme G, De Ridder M (2014) Phase II study of stereotactic body radiotherapy to primary tumor and metastatic locations in oligometastatic nonsmall-cell lung cancer patients. Ann Oncol 25(10):1954–1959CrossRefGoogle Scholar
  11. 11.
    Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, van der Poel HG, van der Kwast TH, Rouviere O, Wiegel T, Mottet N (2016) EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol 71:630–642CrossRefGoogle Scholar
  12. 12.
    Ost P, Bossi A, Decaestecker K, De Meerleer G, Giannarini G, Karnes RJ, Roach M 3rd, Briganti A (2015) Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature. Eur Urol 67(5):852–863CrossRefGoogle Scholar
  13. 13.
    Phillips RM, Hayman J, Tran PT (2018) STOMPing out hormone-sensitive metastases with local therapies in prostate cancer. J Clin Oncol 36(5):435–437CrossRefGoogle Scholar
  14. 14.
    Schweizer MT, Zhou XC, Wang H, Yang T, Shaukat F, Partin AW, Eisenberger MA, Antonarakis ES (2013) Metastasis-free survival is associated with overall survival in men with PSA-recurrent prostate cancer treated with deferred androgen deprivation therapy. Ann Oncol 24(11):2881–2886CrossRefGoogle Scholar
  15. 15.
    Ost P, Decaestecker K, Lambert B, Fonteyne V, Delrue L, Lumen N, Ameye F, De Meerleer G (2014) Prognostic factors influencing prostate cancer-specific survival in non-castrate patients with metastatic prostate cancer. Prostate 74(3):297–305CrossRefGoogle Scholar
  16. 16.
    Sridharan S, Steigler A, Spry NA, Joseph D, Lamb DS, Matthews JH, Atkinson C, Tai KH, Duchesne G, Christie D, Attia J, Holliday EG, Denham JW (2016) Oligometastatic bone disease in prostate cancer patients treated on the TROG 03.04 RADAR trial. Radiother Oncol 121(1):98–102CrossRefGoogle Scholar
  17. 17.
    Ost P, Jereczek-Fossa BA, As NV, Zilli T, Muacevic A, Olivier K, Henderson D, Casamassima F, Orecchia R, Surgo A, Brown L, Tree A, Miralbell R, De Meerleer G (2016) Progression-free survival following stereotactic body radiotherapy for oligometastatic prostate cancer treatment-naive recurrence: a multi-institutional analysis. Eur Urol 69(1):9–12CrossRefGoogle Scholar
  18. 18.
    Muacevic A, Kufeld M, Rist C, Wowra B, Stief C, Staehler M (2013) Safety and feasibility of image-guided robotic radiosurgery for patients with limited bone metastases of prostate cancer. Urol Oncol 31(4):455–460CrossRefGoogle Scholar
  19. 19.
    Muldermans JL, Romak LB, Kwon ED, Park SS, Olivier KR (2016) Stereotactic body radiation therapy for oligometastatic prostate cancer. Int J Radiat Oncol Biol Phys 95(2):696–702CrossRefGoogle Scholar
  20. 20.
    Karnes RJ, Murphy CR, Bergstralh EJ, DiMonte G, Cheville JC, Lowe VJ, Mynderse LA, Kwon ED (2015) Salvage lymph node dissection for prostate cancer nodal recurrence detected by 11C-choline positron emission tomography/computerized tomography. J Urol 193(1):111–116CrossRefGoogle Scholar
  21. 21.
    De Bleser E, Tran PT, Ost P (2017) Radiotherapy as metastasis-directed therapy for oligometastatic prostate cancer. Curr Opin Urol 27(6):587–595CrossRefGoogle Scholar
  22. 22.
    Loo BW Jr, Chang JY, Dawson LA, Kavanagh BD, Koong AC, Senan S, Timmerman RD (2011) Stereotactic ablative radiotherapy: what’s in a name? Pract Radiat Oncol 1(1):38–39CrossRefGoogle Scholar
  23. 23.
    Schick U, Jorcano S, Nouet P, Rouzaud M, Vees H, Zilli T, Ratib O, Weber DC, Miralbell R (2013) Androgen deprivation and high-dose radiotherapy for oligometastatic prostate cancer patients with less than five regional and/or distant metastases. Acta Oncol 52(8):1622–1628CrossRefGoogle Scholar
  24. 24.
    Ingrosso G, Trippa F, Maranzano E, Carosi A, Ponti E, Arcidiacono F, Draghini L, Di Murro L, Lancia A, Santoni R (2017) Stereotactic body radiotherapy in oligometastatic prostate cancer patients with isolated lymph nodes involvement: a two-institution experience. World J Urol 35(1):45–49CrossRefGoogle Scholar
  25. 25.
    Donovan JL, Hamdy FC, Lane JA, Mason M, Metcalfe C, Walsh E, Blazeby JM, Peters TJ, Holding P, Bonnington S, Lennon T, Bradshaw L, Cooper D, Herbert P, Howson J, Jones A, Lyons N, Salter E, Thompson P, Tidball S, Blaikie J, Gray C, Bollina P, Catto J, Doble A, Doherty A, Gillatt D, Kockelbergh R, Kynaston H, Paul A, Powell P, Prescott S, Rosario DJ, Rowe E, Davis M, Turner EL, Martin RM, Neal DE, Protec TSG (2016) Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med 375(15):1425–1437CrossRefGoogle Scholar
  26. 26.
    Crawford ED, Moul JW (2015) ADT risks and side effects in advanced prostate cancer: cardiovascular and acute renal injury. Oncology 29(1):55–58–65–66 (Williston Park) Google Scholar
  27. 27.
    Berkovic P, De Meerleer G, Delrue L, Lambert B, Fonteyne V, Lumen N, Decaestecker K, Villeirs G, Vuye P, Ost P (2013) Salvage stereotactic body radiotherapy for patients with limited prostate cancer metastases: deferring androgen deprivation therapy. Clin Genitourin Cancer 11(1):27–32CrossRefGoogle Scholar
  28. 28.
    Decaestecker K, De Meerleer G, Lambert B, Delrue L, Fonteyne V, Claeys T, De Vos F, Huysse W, Hautekiet A, Maes G, Ost P (2014) Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence. Radiat Oncol 9:135CrossRefGoogle Scholar
  29. 29.
    Steuber T, Jilg C, Tennstedt P, De Bruycker A, Tilki D, Decaestecker K, Zilli T, Jereczek-Fossa BA, Wetterauer U, Grosu AL, Schultze-Seemann W, Heinzer H, Graefen M, Morlacco A, Karnes RJ, Ost P (2018) Standard of care versus metastases-directed therapy for PET-detected nodal oligorecurrent prostate cancer following multimodality treatment: a multi-institutional case-control study. Eur Urol Focus.  https://doi.org/10.1016/j.euf.2018.02.015 CrossRefGoogle Scholar
  30. 30.
    Gan GN, Weickhardt AJ, Scheier B, Doebele RC, Gaspar LE, Kavanagh BD, Camidge DR (2014) Stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving crizotinib. Int J Radiat Oncol Biol Phys 88(4):892–898CrossRefGoogle Scholar
  31. 31.
    Weickhardt AJ, Scheier B, Burke JM, Gan G, Lu X, Bunn PA Jr, Aisner DL, Gaspar LE, Kavanagh BD, Doebele RC, Camidge DR (2012) Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol 7(12):1807–1814CrossRefGoogle Scholar
  32. 32.
    Handy CE, Antonarakis ES (2016) Sequencing treatment for castration-resistant prostate cancer. Curr Treat Options Oncol 17(12):64CrossRefGoogle Scholar
  33. 33.
    Wild AT, Herman JM, Dholakia AS, Moningi S, Lu Y, Rosati LM, Hacker-Prietz A, Assadi RK, Saeed AM, Pawlik TM, Jaffee EM, Laheru DA, Tran PT, Weiss MJ, Wolfgang CL, Ford E, Grossman SA, Ye X, Ellsworth SG (2016) Lymphocyte-sparing effect of stereotactic body radiation therapy in patients with unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 94(3):571–579CrossRefGoogle Scholar
  34. 34.
    Kotecha R, Djemil T, Tendulkar RD, Reddy CA, Thousand RA, Vassil A, Stovsky M, Berglund RK, Klein EA, Stephans KL (2016) Dose-escalated stereotactic body radiation therapy for patients with intermediate- and high-risk prostate cancer: initial dosimetry analysis and patient outcomes. Int J Radiat Oncol Biol Phys 95(3):960–964CrossRefGoogle Scholar
  35. 35.
    Beauval JB, Loriot Y, Hennequin C, Rozet F, Barthelemy P, Borchiellini D, Schlurmann Constans F, Gross E, Maillet D, Pasticier G et al (2018) Loco-regional treatment for castration-resistant prostate cancer: is there any rationale? A critical review from the AFU-GETUG. Crit Rev Oncol Hematol 122:144–149CrossRefGoogle Scholar
  36. 36.
    Bouchelouche K, Choyke PL (2016) PSMA PET in prostate cancer—a step towards personalized medicine. Curr Opin Oncol 28(3):216–221.  https://doi.org/10.1097/CCO.0000000000000277 CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • C. Leigh Moyer
    • 1
  • Ryan Phillips
    • 1
  • Matthew P. Deek
    • 1
  • Noura Radwan
    • 1
  • Ashley E. Ross
    • 2
    • 3
  • Emmanuel S. Antonarakis
    • 3
  • Diane Reyes
    • 2
  • Jean Wright
    • 1
  • Stephanie A. Terezakis
    • 1
  • Daniel Y. Song
    • 1
  • Curtiland DeVille
    • 1
  • Patrick C. Walsh
    • 2
  • Theodore L. DeWeese
    • 1
    • 2
    • 3
  • Michael Carducci
    • 2
    • 3
  • Edward M. Schaeffer
    • 2
    • 3
  • Kenneth J. Pienta
    • 2
    • 3
  • Mario Eisenberger
    • 2
    • 3
  • Phuoc T. Tran
    • 1
    • 2
    • 3
    Email author
  1. 1.Department of Radiation Oncology and Molecular Radiation Sciences, Sidney Kimmel Comprehensive Cancer CenterJohns Hopkins University School of MedicineBaltimoreUSA
  2. 2.Department of UrologyJohns Hopkins University School of MedicineBaltimoreUSA
  3. 3.Department of OncologyJohns Hopkins University School of MedicineBaltimoreUSA

Personalised recommendations